DECEMBER 2013 Summary of Changes to the Queensland Health List of Approved Medicines (LAM)
as recommended by the Queensland Health Medicines Advisory Committee (QHMAC)
ITEM
NUMBER
MEDICINE
DECISION
& DATE
EFFECTIVE
RESTRICTION
CHLORHEXIDINE
aqueous (sterile)
solution 0.1% 100mL
TERBUTALINE sulfate
powder for inhalation
500mcg per dose (100
doses)
ADDED
1 Feb 14
13/100
VITAMIN
COMPOUND WITH
MINERALS - RENAL
(Kidney Vital®)
ADDED
1 Feb 14
Nephrologists or nephrology nurse practitioners for use in patients on dialysis as replacement for the
combination of folic acid, vitamin B group with ascorbic acid and cholecalciferol.”
13/104
CEFEPIME Injection
1g
AMENDED
1 Feb 14
“(a) Specialist Staff and Country Medical Superintendents for infections resistant to other agents
preferably on the advice of an Infectious Diseases Physician or a Clinical Microbiologist.
(b) For patients under the care of Specialist Renal Physicians for empiric treatment of paediatric
peritoneal dialysis peritonitis according to the statewide paediatric clinical pathway.”
When medicines are used in ways other than as specified in the TGA approved product information,
documentation and evaluation should be undertaken with reference to QHMAC’s note in the introductory
pages of the LAM and the CATAG guiding principles for the quality use of off-label medicines
(www.catag.org.au).”
13/101A
DALTEPARIN
SODIUM Prefilled
syringe, single dose
subcutaneous injection
2,500 IU in 0.2mL
AMENDED
1 Feb 14
“Specialist Staff and Country Medical Superintendents for adult use: for prophylaxis of venous
thromboembolism (VTE) & during haemodialysis. When medicines are used in ways other than as
specified in the TGA approved product information, documentation & evaluation should be undertaken
with reference to QHMAC’s note in the introductory pages of the LAM & the CATAG guiding principles
for the quality use of off-label medicines (www.catag.org.au).”
13/106A2
13/106C2
ADDED
1 Feb 14
Page 2 of 3
13/101A
DALTEPARIN
SODIUM Prefilled
syringe, single dose
subcutaneous injection
5,000 IU in 0.2mL
AMENDED
1 Feb 14
“Specialist Staff and Country Medical Superintendents for adult use: for prophylaxis of venous
thromboembolism (VTE) and during haemodialysis; and treatment of VTE. When medicines are used in
ways other than as specified in the TGA approved product information, documentation and evaluation
should be undertaken with reference to QHMAC’s note in the introductory pages of the LAM and the
CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au).”
13/093
KETAMINE Injection
200mg in 2mL
AMENDED
1 Feb 14
(a) For use as a general anaesthetic agent in areas where anaesthesia is delivered;
(b) For use as an analgesic adjuvant under the supervision of an acute pain service, or in emergency
departments, where standard analgesics in appropriate doses are insufficient to control pain;
(c) For use as an analgesic adjuvant in the treatment of persistent pain under the supervision of
specialists in pain medicine and palliative care;
(d) For use in the field by practitioners trained to administer ketamine in emergency situations where
standard anaesthetic and analgesic agents are contraindicated.
When medicines are used in ways other than as specified in the TGA approved product information,
documentation and evaluation should be undertaken with reference to QHMAC’s note in the introductory
pages of the LAM and the CATAG guiding principles for the quality use of off-label medicines
(www.catag.org.au).
CONTROLLED DRUG”
13/101
OFF LABEL
DISCLAIMER which
currently applies to 23
LAM listed medicines
OMEPRAZOLE
SUSPENSION 2mg
per mL, 100mL
AMENDED
1 April 14
13/101B
SEVOFLURANE
INHALATION
ANAESTHETIC
250mL
AMENDED
1 Feb 14
When medicines are used in ways other than as specified in the TGA approved product information,
documentation and evaluation should be undertaken with reference to QHMAC’s note in the introductory
pages of the LAM and the CATAG guiding principles for the quality use of off-label medicines
(www.catag.org.au)
Specialist Staff and Country Medical Superintendents for:
Children (up to the age of 18 years) who require administration via nasogastric or gastrostomy feeding
tubes (which includes nasogastric tube, gastrostomy buttons, gastrojejenal buttons and PEGs).”
“
“Specialist Staff & Country Medical Superintendents (down to a minimum fresh gas flow of one litre per
minute)". When medicines are used in ways other than as specified in the TGA approved product
information, documentation and evaluation should be undertaken with reference to QHMAC’s note in the
introductory pages of the LAM and the CATAG guiding principles for the quality use of off-label
medicines (www.catag.org.au).”
13/103B
OMEPRAZOLE
SUSPENSION 2mg
per mL, 100mL
DEFERRED
13/103A
AMENDED
1 Feb 14
13/105
13/106A1
13/106B
13/106C1
13/102
SODIUM CHLORIDE
0.9% Prefilled syringe
10mL (BD Posiflush
Prefilled Saline
Syringe®)
CHLORHEXIDINE
aqueous (sterile)
solution 0.1% 500mL
GENTAMICIN injection
10mg base in 1mL,
40mg base in 1mL,
60mg base in 1.5mL
DEFERRED
TERBUTALINE sulfate
powder for inhalation
500mcg/ dose (200)
AMPHOTERICIN
Injection 50mg;
DELETED
1 Feb 14
DELETED
1 Feb 14
DELETED
1 Feb 14
NOT
AMENDED
AMPHOTERICIN
Injection, Lipid
Complex
100mg in 2mL;
AMPHOTERICIN
Injection, Liposomal
50mg
7
Standing
agenda
item
CATAG Guiding
principles on OFFLABEL use.
NOTED